GLPG0634: all 50 studies that test it

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsRecruitingNCT07554495Phase 3
• OLE Study With Filgotinib in JIARecruitingNCT07553182Phase 3
• A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative ColitisRecruitingNCT06865417Phase 3
• JAK Inhibitor Dose TAPering Strategy StudyRecruitingNCT06687551Phase 4
• Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)RecruitingNCT06527534Phase 4
• Drug Rediscovery for Rare Immune Mediated Inflammatory DiseasesRecruitingNCT06285539Phase 2
• Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNot yet recruitingNCT05502731Phase 4
• Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)RecruitingNCT04985435Phase 4
• A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionTerminatedNCT05479058Phase 3Results posted
• Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsCompletedNCT04608344Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD TherapyTerminatedNCT04115839Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyTerminatedNCT04115748Phase 3Results posted
• Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedNCT03926195Phase 2Results posted
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionCompletedNCT03417778Phase 1Results posted
• Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)CompletedNCT03285711Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious UveitisTerminatedNCT03207815Phase 2Results posted
• Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseTerminatedNCT03201445Phase 2Results posted
• Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)CompletedNCT03134222Phase 2Results posted
• Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeCompletedNCT03100942Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's DiseaseCompletedNCT03077412Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)CompletedNCT03046056Phase 2Results posted
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisCompletedNCT03025308Phase 3Results posted
• Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedNCT02914600Phase 3Results posted
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedNCT02914561Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisCompletedNCT02914522Phase 3Results posted
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedNCT02889796Phase 3Results posted
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyCompletedNCT02886728Phase 3Results posted
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentCompletedNCT02873936Phase 3Results posted
• Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsCompletedNCT02065700Phase 2Results posted
• Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)CompletedNCT01894516Phase 2Results posted
• Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)CompletedNCT01888874Phase 2Results posted
• Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)TerminatedNCT06222034Phase 1
• Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy SubjectsCompletedNCT06043739Phase 1
• A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisActive, not recruitingNCT05785611Phase 3
• Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to MethotrexateStatus unknownNCT05090410Phase 3
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483700Phase 3
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483687Phase 3
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.TerminatedNCT03320876Phase 2
• A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing SpondylitisCompletedNCT03117270Phase 2
• A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedNCT02914535Phase 3
• Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy SubjectsCompletedNCT02162355Phase 1
• Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT02084199Phase 1
• Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's DiseaseCompletedNCT02048618Phase 2
• A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy SubjectsCompletedNCT01798979Phase 1
• Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01668641Phase 2
• Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy SubjectsCompletedNCT01665924Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy SubjectsCompletedNCT01419990Phase 1
• Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01384422Phase 2
• First-in-Human Single Ascending and Multiple Dose of GLPG0634CompletedNCT01179581Phase 1

← GLPG0634 overview